Flutiform 250+10 mikrogram inhalationsspray, suspension Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

flutiform 250+10 mikrogram inhalationsspray, suspension

paranova danmark a/s - fluticasonpropionat, formoterolfumarat dihydrat - inhalationsspray, suspension - 250+10 mikrogram

Befoair 100+6 mikrog./dosis inhalationsspray, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

befoair 100+6 mikrog./dosis inhalationsspray, opløsning

orion corporation - beclometasondipropionat, formoterolfumarat dihydrat - inhalationsspray, opløsning - 100+6 mikrog./dosis

Befoair 200+6 mikrog./dosis inhalationsspray, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

befoair 200+6 mikrog./dosis inhalationsspray, opløsning

orion corporation - beclometasondipropionat, formoterolfumarat dihydrat - inhalationsspray, opløsning - 200+6 mikrog./dosis

Onivyde pegylated liposomal (previously known as Onivyde) Den Europæiske Union - dansk - EMA (European Medicines Agency)

onivyde pegylated liposomal (previously known as onivyde)

les laboratoires servier - irinotecan anhydrous free-base - bukspyttkjertel-neoplasmer - antineoplastiske midler - behandling af metastatisk adenokarcinom i pancreas, i kombination med 5 fluorouracil (5 fu) og leucovorin (lv), hos voksne patienter, der har udviklet sig efter gemcitabin baseret terapi.

Zydelig Den Europæiske Union - dansk - EMA (European Medicines Agency)

zydelig

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Irinotecan "Fresenius Kabi" 20 mg/ml koncentrat til infusionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

irinotecan "fresenius kabi" 20 mg/ml koncentrat til infusionsvæske, opløsning

fresenius kabi ab - irinotecanhydrochloridtrihydrat - koncentrat til infusionsvæske, opløsning - 20 mg/ml

Serkep 25+125 mikrog/dosis inhalationsspray, suspension Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

serkep 25+125 mikrog/dosis inhalationsspray, suspension

viatris limited - fluticasonpropionat, salmeterolxinafoat - inhalationsspray, suspension - 25+125 mikrog/dosis

Serkep 25+250 mikrog/dosis inhalationsspray, suspension Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

serkep 25+250 mikrog/dosis inhalationsspray, suspension

viatris limited - fluticasonpropionat, salmeterolxinafoat - inhalationsspray, suspension - 25+250 mikrog/dosis

Aforbe 100+6 mikrog/dosis inhalationsspray, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aforbe 100+6 mikrog/dosis inhalationsspray, opløsning

viatris limited - beclometasondipropionat, formoterolfumarat dihydrat - inhalationsspray, opløsning - 100+6 mikrog/dosis

Trimbow Den Europæiske Union - dansk - EMA (European Medicines Agency)

trimbow

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrat, glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.